skynesher/E+ via Getty Images Lyell Immunopharma ( NASDAQ: LYEL ) on Thursday said it would acquire clinical-stage biotechnology firm ImmPACT Bio USA for $30M in cash and 37.5M shares of Lyell common stock. Upon closing, Lyell will acquire worldwide rights to ImmPACT’s pipeline, including the next - generation bispecific CD19/CD20 autologous CAR T-cell.
